Advertisement
BSX vs NTRA
Which Stock Would AI Choose? Boston Scientific (BSX) vs. Natera (NTRA) Stock Comparison
Key Takeaways
- Boston Scientific (BSX) is a large, diversified medical-device leader, while Natera (NTRA) is a faster-growing precision-diagnostics and genetic-testing company.
- BSX delivered strong double-digit revenue growth but saw its shares sell off recently on segment-specific concerns; NTRA has posted accelerating revenue and improving gross margins.
- The two names represent contrasting risk profiles: BSX offers scale and diversification, while NTRA offers higher growth with a still-narrowing profitability path.
- Recent market momentum has favored NTRA, whose relative performance and trend consistency have been stronger over recent months.
- Sector exposure differs sharply, with BSX tied to cardiovascular and surgical devices and NTRA tied to oncology and reproductive health testing.
Introduction
Investors evaluating healthcare stocks often weigh stability against growth. This stock comparison examines two very different businesses operating under the broad healthcare umbrella: BSX, Boston Scientific Corporation, a diversified medical-device manufacturer, and NTRA, Natera, a precision-diagnostics company built around cell-free DNA (cfDNA) testing. The comparison is relevant for traders seeking relative performance signals as well as longer-term investors assessing market positioning, growth drivers, and risk. By reviewing recent performance, momentum, and structural trade-offs, readers can better understand how these two names stack up in the current environment.
BSX Overview and Recent Performance
BSX (Boston Scientific Corporation) is a global medical-technology company whose products span cardiovascular devices, endoscopy, urology, and neuromodulation. The company reported full-year revenue above $20 billion in its most recent fiscal year, up roughly 20% year over year on a reported basis, supported by franchises such as WATCHMAN (a left atrial appendage closure device) and its pulsed field ablation (PFA) portfolio for atrial fibrillation.
Despite strong top-line results, BSX shares have faced notable selling pressure in recent weeks. Sentiment weakened around concerns including sequential softness in U.S. electrophysiology (EP) sales, a modest miss in U.S. WATCHMAN, supply-chain disruptions in urology, and an endoscopy product removal. The company has also pursued merger-and-acquisition (M&A) activity, announcing agreements for strategic acquisitions to expand adjacent markets. Management has guided for organic revenue growth in the low double digits for the current year, but near-term relative performance has lagged the broader market.
NTRA Overview and Recent Performance
NTRA (Natera, Inc.) is a diagnostics company focused on molecular and genetic testing across oncology, women's health, and organ health. Its growth has been driven primarily by Signatera, a minimal residual disease (MRD) test used to monitor cancer patients. In its most recent fiscal year, Natera's revenue rose roughly 35% to about $2.3 billion, while fourth-quarter revenue climbed approximately 40% year over year.
Recent market activity has been constructive for NTRA, with shares generally trending higher as clinical MRD test volumes accelerated by more than 50% year over year and gross margins expanded toward the high-60s percentage range. The company continues to report a GAAP net loss, but losses have narrowed and it has generated positive operating cash flow, improving its financial footing. Strong clinical data readouts and expanding Medicare coverage momentum have reinforced investor confidence, supporting more favorable relative performance in recent weeks.
Trending AI Robots
For traders seeking a systematic edge, Tickeron's Trending AI Robots page offers a curated selection of AI-driven trading bots. Tickeron hosts hundreds of AI trading bots covering thousands of tickers, each with distinct trading styles, strategies, timeframes, performance statistics, and watchlists. Because not every bot is equally suited to shifting market conditions, only the strongest and most relevant performers are featured in the Trending AI Robots section. These bots apply quantitative, pattern-recognition approaches to help identify trading opportunities across names like those discussed in this stock comparison. To explore the current lineup and see which strategies are resonating with today's market, visit the Trending AI Robots page.
Head-to-Head Comparison
The core contrast between these two companies is business model and growth stage. BSX is a mature, diversified device maker generating substantial profitability and cash flow, with growth tied to product innovation and M&A. NTRA is a diagnostics platform earlier in its profitability curve, where revenue growth and gross-margin expansion matter more than current earnings.
Growth drivers also differ. BSX leans on cardiovascular devices and interventional procedures, while NTRA depends on adoption of molecular testing in oncology and reproductive health. Risk factors vary accordingly: BSX faces competitive pressure in EP and supply-chain execution risk, whereas NTRA faces reimbursement and regulatory sensitivity, plus a competitive diagnostics landscape. On recent momentum, NTRA has shown stronger relative performance and a more consistent uptrend, while BSX has experienced a pullback despite solid fundamentals. Market sentiment, as reflected in recent price action, has favored NTRA's growth narrative over BSX's scale-and-diversification story.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative momentum, and catalyst positioning, Tickeron's AI would likely favor NTRA in the current environment. The stock's accelerating revenue growth, improving gross margins, and constructive price trend present a more favorable near-term setup than BSX's recent pullback, which reflects segment-specific headwinds. That said, BSX's diversification and cash-flow strength offer a more stable foundation, meaning the two names may appeal to different risk profiles. Any AI-driven assessment remains probabilistic rather than definitive, grounded in current data and subject to change as market conditions evolve.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BSX is a StrongBuy and NTRA is a StrongBuy.
Momentum Indicator for BSX turns positive, indicating new upward trend
BSX saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In 54 of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at 61%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BSX's RSI Indicator exited the oversold zone, 15 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 58%.
The Moving Average Convergence Divergence (MACD) for BSX just turned positive on October 12, 2026. Looking at past instances where BSX's MACD turned positive, the stock continued to rise in 25 of 44 cases over the following month. The odds of a continued upward trend are 57%.
BSX moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in 199 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
BSX broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BSX entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. BSX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.587) is normal, around the industry mean (2.874). P/E Ratio (17.876) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.618) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (3.117) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Momentum Indicator for NTRA turns positive, indicating new upward trend
NTRA saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 99 similar instances where the indicator turned positive. In 82 of the 99 cases, the stock moved higher in the following days. The odds of a move higher are at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +3.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in 245 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 228 of 286 cases where NTRA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The 10-day RSI Indicator for NTRA moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 25 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 66%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for NTRA turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 33 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 66%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
NTRA broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.762) is normal, around the industry mean (66.046). NTRA's P/E Ratio (-297.311) is considerably lower than the industry average of (2.422). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (17.857) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. NTRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
BSX | NTRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 82 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 97 | 8 | |
SMR RATING 1..100 | 55 | 94 | |
PRICE GROWTH RATING 1..100 | 62 | 34 | |
P/E GROWTH RATING 1..100 | 94 | 90 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (6) in the Biotechnology industry is significantly better than the same rating for BSX (72) in the Medical Specialties industry. This means that NTRA’s stock grew significantly faster than BSX’s over the last 12 months.
NTRA's Profit vs Risk Rating (8) in the Biotechnology industry is significantly better than the same rating for BSX (97) in the Medical Specialties industry. This means that NTRA’s stock grew significantly faster than BSX’s over the last 12 months.
BSX's SMR Rating (55) in the Medical Specialties industry is somewhat better than the same rating for NTRA (94) in the Biotechnology industry. This means that BSX’s stock grew somewhat faster than NTRA’s over the last 12 months.
NTRA's Price Growth Rating (34) in the Biotechnology industry is in the same range as BSX (62) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to BSX’s over the last 12 months.
NTRA's P/E Growth Rating (90) in the Biotechnology industry is in the same range as BSX (94) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to BSX’s over the last 12 months.
| BSX | NTRA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 58% | 1 day ago 66% |
| Stochastic ODDS (%) | 1 day ago 45% | 1 day ago 80% |
| Momentum ODDS (%) | 1 day ago 61% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 57% | 1 day ago 66% |
| TrendWeek ODDS (%) | 1 day ago 57% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 56% | 1 day ago 83% |
| Advances ODDS (%) | 3 days ago 59% | 2 days ago 80% |
| Declines ODDS (%) | 9 days ago 54% | 9 days ago 76% |
| BollingerBands ODDS (%) | 1 day ago 45% | 1 day ago 58% |
| Aroon ODDS (%) | 1 day ago 66% | 1 day ago 80% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BSX’s FA Score shows that 0 FA rating(s) are green while NTRA’s FA Score has 2 green FA rating(s).
- BSX’s FA Score: 0 green, 5 red.
- NTRA’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BSX’s TA Score shows that 4 TA indicator(s) are bullish while NTRA’s TA Score has 4 bullish TA indicator(s).
- BSX’s TA Score: 4 bullish, 4 bearish.
- NTRA’s TA Score: 4 bullish, 4 bearish.
Price Growth
BSX (@Medical/Nursing Services) experienced а +4.24% price change this week, while NTRA (@Medical Specialties) price change was -0.84% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.50%. For the same industry, the average monthly price growth was -10.64%, and the average quarterly price growth was -10.25%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.29%. For the same industry, the average monthly price growth was -6.63%, and the average quarterly price growth was +42.53%.
Reported Earning Dates
BSX is expected to report earnings on Oct 28, 2026.
NTRA is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-3.29% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
BSX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BSX has been closely correlated with ISRG. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BSX jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To BSX | 1D Price Change % | ||
|---|---|---|---|---|
| BSX | 100% | +3.37% | ||
| ISRG - BSX | 71% Closely correlated | +3.67% | ||
| MMSI - BSX | 56% Loosely correlated | +2.78% | ||
| ALC - BSX | 49% Loosely correlated | +4.75% | ||
| MDT - BSX | 46% Loosely correlated | +3.83% | ||
| NTRA - BSX | 45% Loosely correlated | -2.91% | ||
More | ||||
NTRA and
Correlation & Price change
A.I.dvisor indicates that over the last year, NTRA has been loosely correlated with ADPT. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if NTRA jumps, then ADPT could also see price increases.
| Ticker / NAME | Correlation To NTRA | 1D Price Change % | ||
|---|---|---|---|---|
| NTRA | 100% | -2.91% | ||
| ADPT - NTRA | 55% Loosely correlated | -3.63% | ||
| NEO - NTRA | 54% Loosely correlated | -3.81% | ||
| GH - NTRA | 54% Loosely correlated | -2.23% | ||
| ISRG - NTRA | 53% Loosely correlated | +3.67% | ||
| TMO - NTRA | 48% Loosely correlated | -2.52% | ||
More | ||||